
India's Krishna Institute of Medical Sciences Hyderabad orders radiation therapy systems for USD 40 million from Elekta

Thousands of cancer patients to benefit from suite of advanced precision radiation therapy solutions

STOCKHOLM – Elekta (EKTA-B.ST) announced today that it has received an order for approximately USD 40 million from one of India's largest corporate healthcare groups, Krishna Institute of Medical Sciences (KIMS) Hyderabad. The combination of solutions includes Elekta's full suite of hardware and software, such as Elekta Unity MR-Linacs; Esprit (Elekta's latest Leksell Gamma Knife) systems; Versa HD linear accelerators; Flexitron brachytherapy afterloaders; and Elekta One suite of oncology software solutions.

Dr. Bhaskar Rao Bollineni, Chairman and Managing Director of KIMS Hospitals, said: "We are delighted to partner with Elekta to bring these cutting-edge technologies to our patients. These devices and software will enable us to provide more personalized and precise treatments for various types of cancers, while minimizing side effects and improving quality of life. We are committed to offering the best possible care to our patients and investing in innovation that can make a difference."

Approximately 1.3 million people were diagnosed with cancer in India in 2020.¹ KIMS Hyderabad's acquisition of Elekta devices and software will help address many of these cases and improve the availability and quality of cancer care.

Gustaf Salford, Elekta's CEO, said: "We are proud to collaborate with KIMS Hyderabad, one of the leading healthcare providers in India, to deliver our state-of-the-art radiation therapy solutions. We believe that these devices will enhance the clinical capabilities and outcomes of their hospitals and benefit thousands of cancer patients. I look forward to a long-term partnership with KIMS Hyderabad and supporting their vision of providing world-class cancer care."

Established in 2000, KIMS Hyderabad is an Indian hospital chain based in Telangana and operates 12 hospitals across Andhra Pradesh, Telangana, and Maharashtra. The Elekta equipment will be deployed in a phased manner over a period of three years across different KIMS hospitals.

This order was booked in the second quarter of Elekta's 2023/24 fiscal year, and the first installations are expected during the fourth quarter of the 2023/24 fiscal year.

###

¹ Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: [10.3322/caac.21660](https://doi.org/10.3322/caac.21660). Epub ahead of print. PMID: [33538338](https://pubmed.ncbi.nlm.nih.gov/33538338/).

For further information, please contact:

Cecilia Ketels, Head of Investor Relations

Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com

Time zone: CET: Central European Time

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 13:30 CET on November 7, 2023.

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.